Lung-brain axis-generated inflammatory biomarkers in traumatic brain injury and acute respiratory distress syndrome: Role of mechanical ventilation/stress
Open Access
- 1 January 2025
- journal article
- Published by KEAI Publishing in Advances in Biomarker Sciences and Technology
- Vol. 7, 238-247
Abstract
The unmet need for effective therapeutic strategies to address the bidirectional perturbation of the lung-brain axis following traumatic brain injury (TBI) or associated with Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is increasingly recognized. Contributing to this unmet need is the absence of reliable biomarkers that reflect the severity of lung-brain axis disruption. We assessed specific potential lung-brain axis biomarkers in TBI and ALI/ARDS subjects and explored the specific influence of exposure to mechanical ventilation. Serum biomarker levels from TBI (n=97) and ARDS subjects (n=39) and healthy controls (n=46) were analyzed (MesoScale Discovery ELISA) utilizing a critical illness lung-brain axis biomarker panel (CILBA) that included DAMPS (eNAMPT, S100A8), inflammatory cytokines (IL-6, IL-1β, IL-1RA, TNF-α), vascular biomarkers (PSGL-1, ANG-2), and neurotrauma biomarkers (GFAP or Glial fibrillary acidic protein, NFL or neurofilament light chain, Tau). TBI and ARDS subjects demonstrated significant elevations in each biomarker (compared to controls) with two exceptions: PSGL-1 was exclusively elevated in ARDS and GFAP exclusively elevated in TBI. Mechanically ventilated subjects exposed exhibited significantly DAMP, vascular and neurotrauma biomarker elevations compared to unexposed subjects. With the exception of GFAP, Ang-2, and S100A8, biomarker elevations were linked to ICU days or mortality. These results highlight overlapping innate immunity dysregulation as a manifestation of lung-brain axis disruption in both TBI- and ARDS-exposed subjects with amplified dysregulation with mechanical ventilation. Additional longitudinal studies of well-phenotyped TBI and ARDS subjects may substantiate the prognostic value of biomarker analyses in assessing the severity of bidirectional lung-brain axis injuries.Keywords
Funding Information
- National Institutes of Health (R01-HL141387)
- National Institutes of Health (P01-HL126609)
- National Institutes of Health (U01-HL125208)
- National Institutes of Health (R42-HL164300)
- National Institutes of Health (R01NS113969)
This publication has 53 references indexed in Scilit:
- Inhibition of S100A8/A9 ameliorates neuroinflammation by blocking NET formation following traumatic brain injuryRedox Biology, 2025
- Adverse Prehospital Events and Outcomes After Traumatic Brain InjuryJAMA Network Open, 2025
- Disentangling tau: One protein, many therapeutic approachesNeurotherapeutics, 2024
- Blood biomarkers for traumatic brain injury: A narrative review of current evidenceBrain and Spine, 2023
- Targeting SELPLG/P‐selectin glycoprotein ligand 1 in preclinical ARDS: Genetic and epigenetic regulation of the SELPLG promoterPulmonary Circulation, 2023
- Inflammasome activation in traumatic brain injury and Alzheimer's diseaseTranslational Research, 2022
- Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patientsJournal of Neurology, 2021
- The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosisJournal of Molecular Medicine, 2020
- Incidence, Risk Factors, and Outcomes of Ventilator-Associated Pneumonia in Traumatic Brain Injury: A Meta-analysisNeurocritical Care, 2019
- Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 CountriesJAMA, 2016